Cargando…

PB2204: HIGH SERUM FERRITIN AT INITIAL DIAGNOSIS IS A PREDICTOR OF BONE MARROW FIBROSIS IN PH NEGATIVE CHRONIC MYELOPROLIFERATIVE NEOPLASMS

Detalles Bibliográficos
Autores principales:	Leone, Aldo, Reina, Raffaella, Romano, Martina, Muriano, Francesco, Gaeta, Giuseppe, Iannotta, Raffaella, Donnarumma, Giuseppina, Conversano, Italia, Barbato, Serafina, Iula, Rossella, Cacace, Andrea, Martinelli, Vincenzo, Pane, Fabrizio, Pugliese, Novella
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429525/ http://dx.doi.org/10.1097/01.HS9.0000975568.88230.cc

Ejemplares similares

P1050: NEXT GENERATION SEQUECING CONTRIBUTES TO DEFINE PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASM CLINICAL PHENOTYPE
por: Leone, Aldo, et al.
Publicado: (2023)

PB2204: THE ROLE OF HES6 IN NORMAL HUMAN HEMATOPOIESIS
por: De Vos, T., et al.
Publicado: (2022)

PB2260: CIDOFOVIR FOR THE TREATMENT OF ADENOVIRUS INFECTION IN PEDIATRIC PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT): A SINGLE CENTER EXPERIENCE
por: Cacace, F., et al.
Publicado: (2022)

PB2564: COVID-19 AND FERRITIN
por: Kuiavovych, Bohdana, et al.
Publicado: (2023)

P1023: COHORT ANALYSIS OF MPN PATIENTS WITH CONCOMITANT MGUS DIAGNOSIS: A RETROSPECTIVE STUDY
por: Fatigati, C., et al.
Publicado: (2022)

P671: USE OF RT-QPCR VERSUS DIGITAL DROPLET PCR AND EVALUATION OF CD26+ CELLS IN LONG TFR PATIENTS WITH CHRONIC MYELOID LEUKEMIA
por: De Fazio, Laura, et al.
Publicado: (2023)

PB2049: MEXICAN REGISTRY OF MYELOPROLIFERATIVE NEOPLASMS. INITIAL REPORT
por: De La Peña Celaya, J. A., et al.
Publicado: (2022)

PB2030: HYPERCHROMIC ANEMIA AS THE FIRST MANIFESTATION OF MYELOPROLIFERATIVE DISEASE
por: Lepkov, Sergey, et al.
Publicado: (2023)

PB2041: EVALUATION OF THE PROGNOSTIC VALUE OF THROMBOPHILIA MARKERS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS
por: Makarik, T., et al.
Publicado: (2022)

PB2054: HIP AND KNEE OSTEOARTHRITIS IN PHILADELPHIA CHROMOSOME-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
por: Holik, H., et al.
Publicado: (2022)

PB2053: PRIMARY ARTERIAL HYPERTENSION IN MYELOPROLIFERATIVE NEOPLASMS: A SYSTEMATIC REVIEW
por: Gaman, M.-A., et al.
Publicado: (2022)

PB2171: POTENTIAL ROLE OF FACTOR XII POLYMORPHISM IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS
por: Efremova, Elizaveta, et al.
Publicado: (2023)

2204. Pathogen Co-infections and Trends in Influenza-like Illness in PAIVED
por: Richard, Stephanie A, et al.
Publicado: (2022)

PB2234: EFFECT OF HYDROXYUREA ON INFLAMMATORY MARKERS IN PATIENTS WITH BCR-ABL NEGATIVE MYELOPROLIFERATIVE DISEASES
por: Altunok, Oguz, et al.
Publicado: (2023)

PB2212: ABDOMINAL AORTIC CALCIFICATION IN PATIENTS NEWLY DIAGNOSED WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASM
por: Lee, Myung-Won, et al.
Publicado: (2023)

PB2179: ALGORITM OF MOLECULAR GENETIC EXAMINATION OF PATIENTS WITH PH-NEGATIVE CRONIC MYELOPROLIFERATIVE NEOPLASM
por: Voroniak, Myroslav, et al.
Publicado: (2023)

PB2189: UNUSUAL SITE THROMBOSIS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS: THE EXPERIENCE WITH 66 CONSECUTIVE CASES.
por: Morsia, Erika, et al.
Publicado: (2023)

PB2178: OUTCOMES OF REDUCED DOSE TEAM (THIOTEPA, ETOPOSIDE, CYTARABINE, MELPHALAN) PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION FOR HODGKIN AND NON-HODGKIN LYMPHOMA: A MONOCENTRIC EXPERIENCE
por: Di Folca, S., et al.
Publicado: (2022)

PB2058: IMPACT OF COMORBIDITIES AND RESPONSE TO TREATMENT ON THE MPN SAF ASSESSMENT OF PHILADELPHIA CHROMOSOME NEGATIVE MYELOPROLIFERATIVE SYNDROMES.
por: Mohamed, B., et al.
Publicado: (2022)

PB2174: DISSECTING THE MECHANISM OF INTERFERON ALFA (IFNΑ) RESPONSE IN MYELOPROLIFERATIVE NEOPLASM AND IDENTIFICATION OF PREDICTORS OF RESPONSE
por: Soyfer, Eli, et al.
Publicado: (2023)

PB2247: BURDEN OF SYMPTOMS AND SYMPTOM EXPERIENCE OF FILIPINO MYELOPROLIFERATIVE NEOPLASM PATIENTS: A QUALITATIVE PHENOMENOLOGICAL STUDY
por: Mesina, Flordeluna, et al.
Publicado: (2023)

PB2237: NON-THROMBOTIC INCREASED PORTAL VENOUS PRESSURE IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS: IS IT JUST A HYPOTHESIS?
por: Yokus, Osman, et al.
Publicado: (2023)

PB2187: ARTERIAL AND VENOUS THROMBOEMBOLIC COMPLICATIONS IN 832 PATIENTS WITH BCR-ABL-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS (MPN)
por: Wille, Kai, et al.
Publicado: (2023)

PB2227: TRANSFORMATION OF MYELOPROLIFERATIVE NEOPLASMS INTO ACUTE PROMYELOCYTIC LEUKEMIA: SYSTEMATIC REVIEW AND META-ANALYSIS OF CASE REPORTS
por: Găman, Mihnea-Alexandru
Publicado: (2023)

PB2016: HIGH SERUM FERRITIN LEVELS AT DIAGNOSIS PREDICT WORSE PROGNOSIS IN ADVANCED MDS IN CHILDREN.
por: Liu, Chenmeng, et al.
Publicado: (2023)

PB2193: JAK2 V617F MUTATION BURDEN DETECTION AND RELATIONSHIP WITH LABORATORY CHARACTERISTICS IN MYELOPROLIFERATIVE NEOPLASMS
por: MA, Xuefei, et al.
Publicado: (2023)

PB2239: ACQUIRED VON WILLEBRAND DISEASE (AVWD) DIAGNOSTIC PROFILE IN MYELOPROLIFERATIVE NEOPLASIA (MN) PATIENTS IN WESTERN-ESTONIA
por: Vaide, Ines, et al.
Publicado: (2023)

PB2223: CLINICOPATHOLOGICAL, CYTOGENETIC AND MOLECULAR CHARACTERISTICS OF PATIENTS WITH NON-CML MYELOPROLIFERATIVE NEOPLASMS: A SINGLE CENTER STUDY
por: Guntiboina, Vinay Anand, et al.
Publicado: (2023)

PB2175: NEXT-GENERATION SEQUENCING IN THE DIAGNOSIS, PROGNOSIS AND FEATURES OF THE COURSE OF THE DISEASE IN PATIENTS WITH PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
por: Kirienko, Anna, et al.
Publicado: (2023)

PB2040: INTERRELATION BETWEEN JAK2 V617F MUTATION AND THE INCIDENCE OF THROMBOTIC EVENTS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS
por: Nikolova, D., et al.
Publicado: (2022)

PB2219: POLYPHARMACY AND DRUG-TO-DRUG INTERACTIONS MAY HAVE A NEGATIVE EFFECT ON SURVIVAL IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS
por: Krecak, Ivan, et al.
Publicado: (2023)

PB2191: A RETROSPECTIVE MULTI-CENTER STUDY ON DIRECT ORAL ANTICOAGULANT USE IN BCR::ABL1 NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
por: Baysal, Mehmet, et al.
Publicado: (2023)

Further results on the narrow $p\overline{p}$ resonances at 2020 and 2204 MeV
por: Benkheiri, P, et al.
Publicado: (1979)

2204. Microbiology of Pneumonia Due to Co-Infection in the ICU: Impact of Host Immune Status
por: Zelus, Casey, et al.
Publicado: (2019)

2204: Evaluations of physiologic perturbations and their relationship with length of stay in neonatal hypoxic-ischemic encephalopathy
por: Slattery, Susan, et al.
Publicado: (2018)

PB2194: HIGHER JAK2 ALLELE BURDEN IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS IS ASSOCIATED WITH HIGHER PREVALENCE OF CHRONIC KIDNEY DISEASE AND UNFAVORABLE DYNAMICS OF KIDNEY FUNCTION OVER TIME
por: Lucijanic, Marko, et al.
Publicado: (2023)

PB2524: TRIAL IN PROGRESS: THE HIBISCUS-KIDS STUDY, A SINGLE-ARM, OPEN-LABEL, PHASE 1/2 STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF ETAVOPIVAT IN PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE
por: Colombatti, Raffaella, et al.
Publicado: (2023)

2204 Characterizing specialized pro-resolving lipid mediators and synthesis pathways in veterans with peripheral artery disease
por: Ramirez, Joel, et al.
Publicado: (2018)

Rituximab-Containing Risk-Adapted Treatment Strategy in Nodular Lymphocyte Predominant Hodgkin Lymphoma: 7-Years Follow-Up
por: Pugliese, Novella, et al.
Publicado: (2021)

Predicting serum ferritin levels in patients with iron overload treated with the film‐coated tablet of deferasirox during the ECLIPSE study
por: Taher, Ali T., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_utcj905u44dfcb1m3l8o4maiv6